Trial Profile
A Randomized, Double-blind, Controlled, Crossover Study to Evaluate the Sodium Excretion of LCZ696 in Patients With Stable Heart Failure, in Patients With Hypertension, and in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Sacubitril/valsartan (Primary) ; Valsartan
- Indications Hypertension
- Focus Pharmacodynamics
- Sponsors Novartis
- 18 Oct 2012 Planned End Date changed from 1 May 2012 to 1 Oct 2012 as reported by ClinicalTrials.gov.
- 03 May 2012 Planned End Date changed from 1 Aug 2011 to 1 May 2012 as reported by ClinicalTrials.gov.
- 17 May 2011 New trial record